Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
Top Cited Papers
- 9 September 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 86 (5) , 1065-1073
- https://doi.org/10.1189/jlb.0609385
Abstract
TAM and other myeloid-derived tumor infiltrating cells are reviewed as pivotal players in the tumor microenvironment; implications to anti-cancer therapy are described. The microenvironment of solid tumors is characterized by a reactive stroma with an abundance of inflammatory mediators and leukocytes, dysregulated vessels and proteolytic enzymes. TAM, major players in the connection between inflammation and cancer, summarize a number of functions (e.g., promotion of tumor cell proliferation and angiogenesis, incessant matrix turnover, repression of adaptive immunity), which ultimately have an important impact on disease progression. Thus, together with other myeloid-related cells present at the tumor site (Tie2 macrophages and MDSCs), TAM represent an attractive target of novel biological therapies of tumors.Keywords
Funding Information
- Ministry of Health and Istituto Superiore Sanita Italy
This publication has 132 references indexed in Scilit:
- Cancer-related inflammationNature, 2008
- NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1αNature, 2008
- NF-κB and cancer—identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Pathways connecting inflammation and cancerCurrent Opinion in Genetics & Development, 2008
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Immune cells as mediators of solid tumor metastasisCancer and Metastasis Reviews, 2007
- Nuclear factor-κB in cancer development and progressionNature, 2006
- Monocyte and macrophage heterogeneityNature Reviews Immunology, 2005
- Inflammation and cancerNature, 2002
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002